Study of the Effects of Iron on Lung Blood Pressure at High Altitude

Hypertension, Pulmonary Clinical Trial

Official title:

Study of the Effects of Iron Supplementation on High Altitude Pulmonary Hypertension.

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00960921
• Other study ID #: Oxford-Kyrgyzstan-2009
• Status: Withdrawn
• Phase: Phase 2
• First received: August 17, 2009
• Last updated: May 12, 2017

Study information

• Verified date: May 2017
• Source: University of Oxford
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Body iron levels may be important in determining how the blood pressure in the lungs changes in response to low oxygen levels. At high altitude, where oxygen levels are low, some patients develop elevated lung blood pressure. The investigators hypothesize that, in high altitude residents with elevated lung blood pressure, iron supplementation will cause a reduction in lung blood pressure.

Description:

Pulmonary hypertensive disorders frequently complicate hypoxic lung disease and worsen patient survival.

Hypoxia-induced pulmonary hypertension is also a major cause of morbidity at high altitude. Hypoxia causes pulmonary hypertension through hypoxic pulmonary vasoconstriction and vascular remodelling. These processes are thought to be regulated at least in part by the hypoxia-inducible factor (HIF) family of transcription factors, which coordinate intracellular responses to hypoxia throughout the body.

HIF is regulated through a cellular degradation process that requires iron as an obligate cofactor. In cultured cells HIF degradation is inhibited by reduced iron availability (by chelation with desferrioxamine) and potentiated by iron supplementation. In humans, laboratory experiments lasting eight hours have shown that acute iron supplementation blunts the pulmonary vascular response to hypoxia, while acute iron chelation with desferrioxamine enhances the response.

These findings suggest that iron may also affect the pulmonary vascular response to hypoxia over longer time periods. The purpose of this study, which will take place at high altitude in Kyrgyzstan, is to investigate whether iron supplementation can reduce pulmonary artery pressure in patients with established high altitude pulmonary hypertension.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• High altitude natives, currently resident at high altitude

• Pulmonary hypertension (mean pulmonary artery pressure > 25 mmHg)

• Pulmonary artery systolic pressure measurable using Doppler echocardiography

Exclusion Criteria:

• Clinical evidence or history of major co-morbidity

• Recent changes to relevant medications, or taking iron/vitamin supplements

Related Conditions & MeSH terms

• Hypertension
• Hypertension, Pulmonary

Intervention

Drug:
• Iron sucrose
An intravenous infusion of 100 mg of iron is administered on days 0, 4, 8, 12, 16 and 20 of the study, giving a total of six iron infusions for each participant in the iron group over the course of the 28-day study period.
• Normal saline
An intravenous infusion of 100 ml of normal (0.9 %) saline is administered on days 0, 4, 8, 12, 16 and 20 of the study, giving a total of six saline (placebo) infusions for each participant in the saline group over the course of the 28-day study period.

Locations

Country	Name	City	State
Kyrgyzstan	Institute of Molecular Biology and Medicine	Bishkek

Sponsors (2)

Lead Sponsor	Collaborator
University of Oxford	National Center of Cardiology and Internal Medicine, Kyrgyzstan

Country where clinical trial is conducted

Kyrgyzstan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in pulmonary artery systolic pressure		28 days